Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports

23.04.2024 | REVIEW

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

verfasst von: Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D. Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E. Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L. Banna

Erschienen in: Current Oncology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.

Recent Findings

ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.

Summary

ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
Literatur
1.
Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3(4):386–90.PubMedCrossRef
2.
Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073–8.PubMedCrossRef
3.
Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975;35(5):1175–81.PubMed
4.
Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, et al. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem. 1989;32(3):548–55.PubMedCrossRef
5.
Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261(5118):212–5.PubMedCrossRef
6.
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Mylotarg Study Group, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.
7.
Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.PubMedCrossRef
8.
Norsworthy KJ, Ko CW, Lee JE, Liu J, John CS, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23(9):1103–8.PubMedPubMedCentralCrossRef
9.
Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.PubMedCrossRef
10.
Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.PubMedPubMedCentralCrossRef
11.
Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436–41.PubMedCrossRef
12.
Chang E, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(4):922–7.PubMedCrossRef
13.
14.
15.
16.
Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 Update. Eur Urol. 2022;82(5):529–42.PubMedCrossRef
17.
18.
Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open. 2022;7(6):100634.PubMedPubMedCentralCrossRef
19.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, STAR Investigators, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023;24(3):213–27.
20.
Aweys H, Lewis D, Sheriff M, Rabbani RD, Lapitan P, Sanchez E, et al. Renal cell cancer - insights in drug resistance mechanisms. Anticancer Res. 2023;43(11):4781–92.PubMedCrossRef
21.
Boussios S, Devo P, Goodall ICA, Sirlantzis K, Ghose A, Shinde SD, et al. Exosomes in the diagnosis and treatment of renal cell cancer. Int J Mol Sci. 2023;24(18):14356.PubMedPubMedCentralCrossRef
22.
Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, et al. Antibody-based therapeutics for the treatment of renal cell carcinoma: challenges and opportunities. Oncologist. 2023;28(4):297–308.PubMedPubMedCentralCrossRef
23.
Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, et al. Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res. 2018;24(18):4399–406.PubMedPubMedCentralCrossRef
24.
McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, et al. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020;38(6):1807–14.PubMedPubMedCentralCrossRef
25.
Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84(2):176–90.PubMedCrossRef
26.
27.
Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, et al. EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2022;81(1):95–103.PubMedCrossRef
28.
Parent P, Marcq G, Adeleke S, Turpin A, Boussios S, Rassy E, et al. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer. Ther Adv Med Oncol. 2023;15:17588359231192402.PubMedPubMedCentralCrossRef
29.
Santini D, Banna GL, Buti S, Isella L, Stellato M, Roberto M. Navigating the rapidly evolving advanced urothelial carcinoma treatment landscape: insights from Italian Experts. Curr Oncol Rep. 2023;25(11):1345–62.PubMedPubMedCentralCrossRef
30.
Uccello M, Adeleke S, Moschetta M, Ghose A, Boussios S. Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence. Ann Palliat Med. 2023;12(6):1345–54.PubMedCrossRef
31.
Rebuzzi SE, Banna GL, Murianni V, Damassi A, Giunta EF, Fraggetta F, et al. Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: a review of the current evidence. Cancers (Basel). 2021;13(21):5517.PubMedCrossRef
32.
Maffezzoli M, Campobasso D, Rebuzzi SE, Banna GL, Fornarini G, Signori A, et al. Prognostic models for patients with metastatic urothelial carcinoma: why use them? Minerva Urol Nephrol. 2023;75(4):419–21.PubMedCrossRef
33.
Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003–13.PubMedCrossRef
34.
Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, et al. Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020;21(15):5390.PubMedPubMedCentralCrossRef
35.
•• Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. This was the phase II EV-201 trial which led to accelerated approval of EV in mUC after progression on platinum chemotherapy and ICI.PubMedPubMedCentralCrossRef
36.
• Yu EY, Petrylak DP, O’Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–82. This trial demonstrated the benefit of EV in cisplatin eligible mUC patients as evidenced by cohort 2.PubMedCrossRef
37.
•• Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125–35. This was the landmark phase III EV-301 trial which led to full FDA approval of EV in mUC after progression on platinum chemotherapy and ICI.PubMedPubMedCentralCrossRef
38.
39.
• Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047–54. This emphasises on 2 years of follow-up from the EV-301 cohort confirming a significantly meaningful and maintained benefit of EV.PubMedCrossRef
40.
•• O’Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41(25):4107–17. This was the phase Ib/II EV-103 trial which formed the basis of accelerated FDA approval for the use of combination EV and pembrolizumab for mUC patients ineligible for platinum-based chemotherapy.PubMedPubMedCentralCrossRef
41.
Powles TB, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+ P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34:S1340.CrossRef
42.
Van Der Heijden MS, Powles T, Gupta S, Bedke J, Kikuchi E, De Wit R, et al. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study. J Clin Oncol. 2024;42(4):LBA530.CrossRef
43.
Avellini C, Licini C, Lazzarini R, Gesuita R, Guerra E, Tossetta G, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642–53.PubMedPubMedCentralCrossRef
44.
•• Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85. This was the phase II TROPHY trial which formed the basis of accelerated FDA approval of SG use in mUC.PubMedPubMedCentralCrossRef
45.
Grivas P, Tagawa ST, Bellmunt J, De Santis M, Duran I, Goebell PJ, et al. TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J Clin Oncol. 2021;39(6):TPS498.CrossRef
46.
• Sheng X, Zhou L, He Z, Guo H, Yan X, Li S, et al. Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2021;40(16):4518. This phase II study paved the way for DV combination therapy with toripalimab in mUC.
47.
Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J Clin Oncol. 2023: JCO2202912
48.
•• McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, et al. The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024;35(1):91–7. This revolutionary phase I trial was the first to investigate the use of multiple ADCs in combination treatment.PubMedCrossRef
49.
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.PubMedCrossRef
50.
Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020;8(2):209–30.PubMedPubMedCentralCrossRef
51.
Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci. 2021;22(18):9783.PubMedPubMedCentralCrossRef
52.
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, STAMPEDE investigators, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443–56.
53.
Cornford P, van den ergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79(2):263-282
54.
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–80.PubMedPubMedCentral
55.
56.
Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016;34(12):530.e15-530.e21.PubMedCrossRef
57.
•• Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020;80(1):99–108. This is a significant positive phase 2 trial of an ADC against PSMA following ARPI therapy in mCRPC.PubMedCrossRef
58.
de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, et al. Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide. Clin Cancer Res. 2021;27(13):3602–9.PubMedCrossRef
59.
Shen J, Pachynski R, Nordquist LT, Adra N, Bilen MA, Aggarwal R, et al. 1804P APEX-01: First-in-human phase I/II study of ARX517 an anti-prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2023;34:S974–5.CrossRef
60.
•• Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, et al. Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(36):3518–27. This is a significant positive phase 1 trial of an ADC against STEAP1, a strong putative target in mCRPC.PubMedPubMedCentralCrossRef
61.
• Lang J, Tagawa ST, Slovin S, Emamekhoo H, Rathkopf D, Abida W, et al. 1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). Ann Oncol. 2022;33:S1188. This phase II study of SG in mCRPC showed positive results and potential as an emerging ADC in prostate cancer.CrossRef
62.
• Aggarwal RR, Vuky J, VanderWeele DJ, Rettig M, Heath EI, Beer TM, Liu B, et al. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(16):3001. This positive trial shows how CD46 is a putative target other than PSMA and STEAP1 and the potential of FOR46 as an emerging ADC.CrossRef
63.
Shenderov E, Mallesara GH, Wysocki PJ, Xu W, Ramlau R, Weickhardt AJ, et al. Antonarakis ES. 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion. Ann Oncol. 2021;32:S657-9.CrossRef
64.
65.
Sharma A, Morrison L, Milic M, Ghose A, Gogbashian A, Vasdev N, et al. A north-west London experience of the impact of treatment related toxicity on clinical outcomes of elderly patients with germ cell tumors. Cancers (Basel). 2022;14(20):4977.PubMedCrossRef
66.
Mérida-García A, Díaz-Serrano A, Bernard B, Del Mar GM, de Velasco G, Sepúlveda JM, et al. Update on the management of patients with intermediate and poor-risk testicular germ cell tumors and new biological insights. Cancer Treat Res Commun. 2019;19:100117.PubMedCrossRef
67.
Alifrangis C, Lucas O, Benafif S, Ansell W, Greenwood M, Smith S, et al. Management of late relapses after chemotherapy in testicular cancer: optimal outcomes with dose-intense salvage chemotherapy and surgery. Eur Urol Focus. 2021;7(4):835–42.PubMedCrossRef
68.
Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzù D, Nicolai N, et al. Brentuximab vedotin in CD30-expressing germ cell tumors after chemotherapy failure. Clin Genitourin Cancer. 2016;14(4):261-264.e4.PubMedCrossRef
69.
Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, et al. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. Invest New Drugs. 2021;39(6):1656–63.PubMedPubMedCentralCrossRef
Metadaten
Titel
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
verfasst von
Aruni Ghose
Patricia Lapitan
Vedika Apte
Adheesh Ghosh
Abhinav Kandala
Sreejana Basu
Jo Parkes
Sayali D. Shinde
Stergios Boussios
Anand Sharma
Prantik Das
Nikhil Vasdev
Sara E. Rebuzzi
Yüksel Ürün
Ravindran Kanesvaran
Akash Maniam
Giuseppe L. Banna
Publikationsdatum
23.04.2024
Verlag
Springer US
Erschienen in
Current Oncology Reports
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01524-7

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise